Patent application number | Description | Published |
20080199503 | Pharmaceutical Compositions Preparation of Peptides, Secreted by the Snake Venom Glands, Particularly of Bothrops Jararaca, Vasopeptidases Inhibitors, Evasins, Their Analogues, Derivatives and Products Associated, Thereof, for Development of Applications and Use in Chronic-Degenerative Diseases - The present invention is characterized by the process of preparation of pharmaceutical compositions for the development of applications of the Evasins and their structural and/or conformational analogues in chronic-degenerative diseases. It is further characterized by the process of preparation of pharmaceutical compositions and related products of the Evasins peptides and their structural and/or conformational analogues in using the cyclodextrins, its derivatives, liposomes and biodegradable polymers and/or mixture of these systems. The invention is further characterized by the increased efficacy of these peptides and their analogues included in cyclodextrins, when administered to rats. This characterizes an increased biodisponibility of these peptides and their analogues using the compositions of the present invention. | 08-21-2008 |
20090017042 | PROCESS FOR THE DETERMINATION OF THE PRIMARY STRUCTURE OF THE MESSENGER RNA CODING FOR THE HUMAN RECOMBINANT ENDOOLIGOPEPTIDASE A (HEOPA) [AF217798] - This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon activity or its activity as soluble peptide receptor; obtaining and using of the specific antibodies and inhibitors of its oligopeptide binding activity, as agonists, competitors and antagonists, which are able to disturb its interaction and the complex formation with other proteins. The invention also refers to the application of the natural and recombinant protein, chemically or genetically modified which aim is the diagnosis and/or the application in congenital, infectious and degenerative pathologic conditions of the central nervous system, and for psychiatric and behavioral dysfunctions. It is also proposed the application of the inhibitors and competitors for the interaction of EOPA with ligands, including antibodies or their derivatives, for the treatment of tissular and neurodegenerative pathologies. | 01-15-2009 |
Patent application number | Description | Published |
20100316750 | CHOLESTEROL LOWERING SUPPLEMENT - The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as a suitable composition comprising (a) one or more phytosterols and/or phytostanols capable of reducing cholesterol absorption in the intestine and/or one or more soluble fibres capable of inhibiting ileal bile acid absorption, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions (b) and (c) is preferably derived from plants. | 12-16-2010 |
20120252723 | Regulating the Amino Acid Pool Used for the Acute-Phase Protein Synthesis - The present invention is directed at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of inflammation or infection, wherein the combination is to be administered enterally and at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of an imbalance in the metabolic use of amino acid resources from the body or from nutrition in a subject having an inflammation or an infection, wherein the combination is to be administered enterally. | 10-04-2012 |
20130219987 | Novel Glucose Tolerance Test and Composition for Use - The present invention relates to a liquid nutritional composition, to a liquid nutritional composition for use in a diagnostic method for screening of a glucose-intolerant condition, to a kit for screening of a glucose-intolerant condition, and to a diagnostic method for screening a mammal for a glucose-intolerant condition. Furthermore, it refers to a liquid nutritional composition for use as a standard reference nutrition, such as for classification of postprandial glucose responses of different nutritional compositions. The liquid nutritional composition comprises protein, fat, digestible carbohydrate and dietary fibre, wherein the digestible carbohydrate comprises at least 90 weight % of glucose units, based on total digestible carbohydrate mass and preferably is substantially free of fructose. | 08-29-2013 |